Shanghai Shen Lian Biomedical (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint

Zhitong Finance APP News, Shenlian Biotechnology (688098.SH) announced that the Phase II clinical study of UB-221 injection, a Class 1 biologic independently developed by its controlled subsidiary Yangzhou Shizhiyuan Biotechnology Co., Ltd. ("Shizhiyuan"), for the treatment of chronic spontaneous urticaria (CSU) "A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in Patients with Chronic Spontaneous Urticaria (CSU)" has met its primary endpoint and achieved positive topline results.